Post-transplant malignancies in minority populations

In Vivo

Volumn 10, Issue 2, 1996, Pages 237-240

  Odocha, O ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Minorities; Post transplant malignancies; Transplantation

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER REGISTRY; ETHNIC GROUP; HEAD AND NECK CANCER; HUMAN; MORBIDITY; ORGAN TRANSPLANTATION; PREVALENCE; SKIN CANCER; UNITED STATES; UROGENITAL TRACT CANCER;

EID: 0029936977     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Burkitt DP: Relationships between Malignant and Non-Malignant Diseases of Western Culture. In: Etiology of Cancer in Man, 1989: Ch. 2, P3-6; Levine, AS (ed). Kluwer Academic Publ, Dordrecht.
2. Burkitt DP: An Approach to the Reduction of the Most Common Western Cancers. Arch Surg 126: 345-347, 1991.
3. Hargreaves MK, Ahmed OI, Semenya KA et al: Nutrition and Cancer Risk: Assessment and Preventive Program Strategies for Black Americans. In: Minorities and Cancer. 1989: Ch 7, p77-94 Jones, LA; (ed). Springer-Verlag, New York.
4. Schwartz RS: Immunoregulation, Oncogenic Viruses, and Malignant Lymphomas. Lancet June 10: 1266-1269, 1972.
5. Kaiser HE: Neoplasms Induced by Non-Cancer Therapies. In: Etiology of Cancer in Man, 1989: Ch 21, P207-211; Levine, AS (ed). Kluwer Academic Publ, Dordrecht.
6. Penn I: Transplantation Oncology: The Next Frontier. In: Intra-Abdominal Organ Transplantation 2000. 1994: Ch. 13, p189-204; Sher LS; Makowka, L (ed). RG Landes Co. Publ.
7. Freeman HP: Cancer in the Socioeconomically Disadvantaged. Adapted from: Cancer in the Economically Disadvantaged; Cancer 64(suppl): 324-334, 1989.
8. Baquet CR, Horm JW, Gibbs, T et al: Socioeconomic Factors and Cancer Incidence Among Blacks and Whites. J Nat Cancer Inst 83 (8): 551-557, 1991.
9. Jepson C, Kessler LG, Portnou B et al: Black-White Differences in Cancer Prevention Knowledge and Behaviour. Am J Publ Health 81(4): 501-504, 1991.
10. Wingo PA, Tong T, Bolden S: Cancer Statistics, 1995. CA-Cancer J Clin 45(1): 8-30,
11. Liebelt AG: Malignant Neoplasms in Organ Transplant Recipients. In: Etiology of Cancer in Man 1989: Ch 16, p136-167; Levine, AS (ed), Kluwer Academic Publ, Dordrecht.
12. Malatack JJ, Gartner JC, Urbach AH et al: Orthotopic Liver Transplantation, Epstein-Barr Virus, Cyclosporine, and Lymphoproliferative Disease: A growing Concern. J Ped 118: 667-675, 1991.
13. Sheil AGR: Complications of Immunosuppressionin Renal Allograft Recipient: Malignancy Clin Transplantation (Spec. issue) 5: 573-579, 1991.
14. Nalesnik MA. Demetris AJ, Fung, JJ et al: Lymphbproliferative Disorders Arising Under Immunosuppression With FK-506: Initial Observations in a Large Transplant Population. Transplant Proc 23(1): 1108-1110, 1991.
15. Euvrard S, Chardonnet Y, Pouteil-Noble CP et al: Skin Malignancies and Human Papillomaviruses in Renal Transplant Recipients. Transplant Proc 25(1): 1392-1393, 1993.
16. Penn I: Malignancy. Surg Clin NA 74(5): 1247-1257, 1994.
17. Data On File: UNOS Update 11(7): 26-27, 1995.
18. Data on File: Cancer Facts and Figures -1994. Am Cancer Soc Publ. p1-28
19. Gruber SA, Skjei KL, Sothern RB et al: Cancer Development in Renal Allograft Recipients Treated with Conventional and Cyclosporine Immunosuppression. Transplant Proc 23(1): 1104-1105, 1991.
20. Shell AGR, Disney APS, Mathew TH et al: De Novo Malignancy Emerges as a Major Cause of Morbidity and Late Failure in Renal Transplantation. Transplant Proc 25(1): 1383-1384, 1993.
21. Penn I: Malignancies Associated with Immunosuppressive or Cytotoxic Therapy. Surgery 83(5): 492-499, 1978.
22. Penn I: Cancers Following Cyclosporine Therapy. Transplantation 43(1): 32-35, 1987.
23. Penn I: The Changing Pattern of Posttransplant Malignancies. Transplant. Proc 23(1): 1101-1103, 1991.
24. Penn I: Personal Communication.
25. Odocha O, Rivadeneira D, Callender CO: Malignant Neoplasms in African-Americans Following Solid Organ Transplantation: A 20-year Single Center Experience. Proc Am Assoc Cancer Res 36(3): 244 (Abstract), 1995.
26. Penn I: Cancer is a Complication of Severe Immunosuppression. Surg Gyne Obstet 162: 603-609, 1986.
27. Tage-Jensen U, Schlichting P, Thomsen G et al: Malignancies Following Long-term Azathioprine Treatment in Chronic Liver Disease. Liver 7: 81-83, 1987.
28. Batiuk TD, Barry JM, Bennett WM et al: Incidence and Type of Cancer Following the Use of OKT3: A Single Center Experience With 557 Organ Transplants. Transplant Proc 25(1): 1391, 1993.
29. Dresdale AR, Lutz S, Drost C et al: Prospective Evaluation of Malignant Neoplasms in Cardiac Transplant Recipients Uniformly Treated With Prophylactic Antilymphocyte Globulin. J4 Thoracic Cardio Vasc Surg 706(6): 1202-1207, 1993.
30. Penn I: Effect of Immunosuppression on Preexisting Cancers. Transplant Proc 25(1): 1380-1382, 1993.
31. Starzl TE,Porter KA, Iwatsuki S et al: Reversibility of Lymphomas and Lymphoproliferative Lesions Developing Under Cyclosporine-Steroid Therapy. Lancet March 17: 583-587, 1984.
32. Lindholm A, Welsh M, Alton C et al: Demographic Factors Influencing Cyclosporine Pharmacokinetic Parameters in Patients With Uremia: Racial Differences in Bioavailability. Clin Pharmacol Ther 52(4): 359-371, 1992.
33. Qunibi WY, Barri Y, Alfurayh O et al: Kaposi's Sarcoma in Renal Transplant Recipients: A Report on 26 Cases From a Single Institution. Transplant Proc 25(1): 1402-1405, 1993.
34. Bronowski J: The Evolution and Power of Symbolic Language. In: The Origins of Knowledge and Imagination. 1978: Ch 2: P21-39; Bronowski J (ed). Yale University Press.
35. Clendeninn NJ: Chemotherapy For Minorities and the Drug Development Process. In: Minorities and Cancer. 1989: Ch. 21; 247-251. Jones, LA; (ed). Springer-Verlag, New York.
36. Vallbona C: The role of Primary Care Physicians in Primary and Secondary Prevention of Cancer in Minority Persons. In: Minorities and Cancer. 1989: Ch 24; P271-278. Jones, LA; (ed). Springer-Verlag, New York.